PHL: Powered Exoskeleton
What it covers
A powered exoskeleton is a prescription device that is composed of an external, powered, motorized orthosis that is placed over a person's paralyzed or weakened lower extremity limb(s) for medical purposes.
FDA’s definition of product code PHL, from the Product Classification database.
Recent clearances
| 510(k) | Device | Applicant | Decision | Type |
|---|---|---|---|---|
| K254198 | Trexo Theo | Trexo Robotics, Inc. | Sep 2, 2026 | Traditional |
| K260381 | Eve | Wandercraft SAS | Aug 3, 2026 | Traditional |
| K250904 | Atalante X | Wandercraft SAS | Oct 24, 2025 | Traditional |
| K241822 | ReWalk® 7 Personal Exoskeleton (50-20-0005) | Rewalk Robotics Ltd. Dba Lifeward | Mar 12, 2025 | Traditional |
| K233695 | Medical HAL Lower Limb Type (HAL-ML) | Cyberdyne, Inc. | May 7, 2024 | Traditional |
| K232077 | Atalante X | Wandercraft SAS | Dec 13, 2023 | Traditional |
| K221696 | ReWalk P6.0 | Re Walk Robotics , Ltd. | Mar 2, 2023 | Traditional |
| K221859 | Atalante | Wandercraft SAS | Dec 29, 2022 | Traditional |
| K220988 | EksoNR | Ekso Bionics, Inc. | Jun 9, 2022 | Traditional |
| K213452 | GEMS-H | Samsung Electronics Co., Ltd. | Apr 21, 2022 | Traditional |
Clearances by year
26 PHL 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.
| Year | Clearances | Median days to decision |
|---|---|---|
| 2026 (so far) | 2 | 216 |
| 2025 | 2 | 237 |
| 2024 | 1 | 172 |
| 2023 | 2 | 209 |
| 2022 | 3 | 177 |
| 2021 | 1 | 408 |
| 2020 | 4 | 110 |
| 2019 | 2 | 132 |
| 2018 | 2 | 145 |
| 2017 | 2 | 149 |
| 2016 | 4 | 145 |
| 2014 | 1 | 374 |
Who submits
15 applicants cleared a PHL device since 2011. 42% of the clearances went to applicants in United States, then France (15%), Israel (15%) and Japan (15%). By type: Traditional 92%, Direct 4% and Special 4%.
| Applicant | Clearances since 2011 |
|---|---|
| Ekso Bionics, Inc. | 4 |
| Wandercraft SAS | 4 |
| Cyberdyne, Inc. | 3 |
| Re Walk Robotics , Ltd. | 3 |
| Parker Hannifin Corporation | 2 |
| Argo Medical Technologies, Inc. | 1 |
| B-Temia, Inc. | 1 |
| Exoatlet Asia Co. , Ltd. | 1 |
How FDA classifies it
Class II (special controls). The special controls for this device are:
(1) Elements of the device materials that may contact the patient must be demonstrated to be biocompatible.
(2) Appropriate analysis/testing must validate electromagnetic compatibility/interference (EMC/EMI), electrical safety, thermal safety, mechanical safety, battery performance and safety, and wireless performance, if applicable.
(3) Appropriate software verification, validation, and hazard analysis must be performed.
(4) Design characteristics must ensure geometry and materials composition are consistent with intended use.
(5) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. Performance testing must include:
(i) Mechanical bench testing (including durability testing) to demonstrate that the device will withstand forces, conditions, and environments encountered during use;
(ii) Simulated use testing (i.e., cyclic loading testing) to demonstrate performance of device commands and safeguard under worst case conditions and after durability testing;
(iii) Verification and validation of manual override controls are necessary, if present;
(iv) The accuracy of device features and safeguards; and
(v) Device functionality in terms of flame retardant materials, liquid/particle ingress prevention, sensor and actuator performance, and motor performance.
(6) Clinical testing must demonstrate a reasonable assurance of safe and effective use and capture any adverse events observed during clinical use when used under the proposed conditions of use, which must include considerations for:
(i) Level of supervision necessary, and
(ii) Environment of use (e.g., indoors and/or outdoors) including obstacles and terrain representative of the intended use environment.
(7) A training program must be included with sufficient educational elements so that upon completion of training program, the clinician, user, and companion can:
(i) Identify the safe environments for device use,
(ii) Use all safety features of device, and
(iii) Operate the device in simulated or actual use environments representative of indicated environments and use.
(8) Labeling for the Physician and User must include the following:
(i) Appropriate instructions, warning, cautions, limitations, and information related to the necessary safeguards of the device, including warning against activities and environments that may put the user at greater risk.
(ii) Specific instructions and the clinical training needed for the safe use of the device, which includes:
(A) Instructions on assembling the device in all available configurations;
(B) Instructions on fitting the patient;
(C) Instructions and explanations of all available programs and how to program the device;
(D) Instructions and explanation of all controls, input, and outputs;
(E) Instructions on all available modes or states of the device;
(F) Instructions on all safety features of the device; and
(G) Instructions for properly maintaining the device.
(iii) Information on the patient population for which the device has been demonstrated to have a reasonable assurance of safety and effectiveness.
(iv) Pertinent non-clinical testing information (e.g., EMC, battery longevity).
(v) A detailed summary of the clinical testing including:
(A) Adverse events encountered under use conditions,
(B) Summary of study outcomes and endpoints, and
(C) Information pertinent to use of the device including the conditions under which the device was studied (e.g., level of supervision or assistance, and environment of use (e.g., indoors and/or outdoors) including obstacles and terrain).
From 21 CFR 890.3480. Special controls are the requirements a 510(k) must show it meets.
Standards
21 CFR 890.3480 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent PHL clearances declared.
Ask about PHL
Questions about PHL
What is FDA product code PHL?
Product code PHL, “Powered Exoskeleton” in FDA's classification database, is a Class II device type under 21 CFR 890.3480 (powered lower extremity exoskeleton), reviewed by FDA's Physical Medicine panel. FDA's 510(k) database lists 26 clearances under PHL, 26 of them since 2011.
How many 510(k) clearances are there under PHL?
FDA’s 510(k) database listed 26 clearances under PHL as of Oct 29, 2026, 26 of them decided since 2011; the most recent decision was Sep 2, 2026. The Predicate Finder searches the live database.
How long does FDA take to clear a PHL 510(k)?
For the 4 PHL clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 233 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.
Which companies have the most PHL clearances?
Since 2011: Ekso Bionics, Inc. (4), Wandercraft SAS (4), Cyberdyne, Inc. (3), Re Walk Robotics , Ltd. (3) and Parker Hannifin Corporation (2). 15 applicants have cleared a PHL device in that time.